Small Cell Lung Cancer clinical trials

Explore recruiting small cell lung cancer clinical trials.

Recruiting small cell lung cancer studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Small Cell Lung Cancer trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A multicenter single-arm phase II interventional study to evaluate the activity and safety of the combination of Platinum-Pemetrexed based chemotherapy plus Lorlatinib in ALK positive Non-Small Cell Lung Cancer (NSCLC) with exclusively extracranial disease progression on Lorlatinib

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

Randomized, Multicenter, Phase III, Open-Label Study of Alectinib Versus Crizotinib In Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer

Poland, Spain, Portugal, Italy

Therapeutic confirmatory (Phase III) EU CTIS Study details

Neoadjuvant nivolumab combination treatment in resectable non-small cell lung cancer patients: Defining optimal combinations and determinants of immunological response (NEOpredict-Lung)

Netherlands, Germany, Belgium

Therapeutic exploratory (Phase II) EU CTIS Study details

Preoperative amivantamab or amivantamab and carboplatin/pemetrexed treatment in patients with resectable non-small-cell lung cancer harboring oncogenic EGFR mutations (NEOpredict-EGFR)

Germany, Belgium, Netherlands

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab Plus Carboplatin and Etoposide with or Without Tiragolumab (Anti-Tigit Antibody) in Patients with Untreated Extensive-Stage Small Cell Lung Cancer

Greece, Italy, Poland

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Multicenter, Randomized, Double-blind Trial to Demonstrate Similar Efficacy, Safety, and Immunogenicity of FYB206 (Keytruda Biosimilar Candidate) in Comparison to Keytruda (Pembrolizumab) as an Add-on to Chemotherapy in Treatment-naïve Patients with Metastatic Non-squamous Non-small Cell Lung Cancer (LOTUS)

Romania, Bulgaria, Poland

Therapeutic confirmatory (Phase III) EU CTIS Study details

Small Cell Lung Cancer trials by city

Small Cell Lung Cancer in Toronto Small Cell Lung Cancer in Vancouver Small Cell Lung Cancer in Montreal Small Cell Lung Cancer in Calgary Small Cell Lung Cancer in Edmonton Small Cell Lung Cancer in Ottawa Small Cell Lung Cancer in Winnipeg Small Cell Lung Cancer in Quebec City Small Cell Lung Cancer in Hamilton Small Cell Lung Cancer in Kitchener Small Cell Lung Cancer in London Small Cell Lung Cancer in Halifax Small Cell Lung Cancer in New York Small Cell Lung Cancer in Los Angeles Small Cell Lung Cancer in Chicago Small Cell Lung Cancer in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease